News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Quotient Clinical Announces RapidFACT Collaboration With Pulmatrix to Develop a New Bronchodilator Therapy for COPD

8/13/2013 8:59:43 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

13 August 2013 -- Quotient Clinical today announced a collaboration with Pulmatrix Inc, a Massachusetts’s based biotech company, to support the development of PUR0200. The new bronchodilator therapy for the treatment of chronic obstructive pulmonary disease (COPD) and the first small molecule product to emerge from Pulmatrix’s novel inhaled iSPERSETM technology platform.

Quotient will employ its RapidFACTTM (Rapid Formulation development And Clinical Testing) service to manufacture the spray dried PUR0200 product in ‘real-time’ to support the Phase 1B clinical study in COPD patients. This capability allows within-protocol adjustment of the formulation composition in response to arising safety, pharmacokinetic and pharmacodynamic data to optimize performance. The clinical study is being performed at the Quotient Clinical site in Nottingham, England and in conjunction with Professor David Singh at the Medicines Evaluation Unit in Manchester, England.

Mark Egerton, Managing Director of Quotient Clinical, commented: “We are delighted that Pulmatrix has chosen to utilise our RapidFACT service to support the development PUR0200. We have proven that RapidFACT can shorten timelines and reduce costs in early development, which ultimately contributes to enhancing R&D productivity. This particular study also demonstrates our ability to manufacture and supply drug product in real time to other clinical centres of excellence that specialise in specific disease indications and endpoints.”

For further information about Quotient Clinical, visit

About Quotient Clinical

Quotient Clinical has over 20 years’ experience delivering high quality data to provide innovative early drug development solutions to pharmaceutical and biotechnology clients worldwide, including 17 of the top 20 pharmaceutical companies. Our expertise in Exploratory Clinical Pharmacology, Drug Product Optimisation, and 14C Enabled Drug Development, underpinned by our unique Translational Pharmaceutics™ and Synthesis-to-Clinic™ delivery platforms, adds significant value to client development programs.

For further information, visit

About Pulmatrix

Pulmatrix, Inc., is a clinical stage biotechnology company developing and commercializing a novel inhaled dry powder drug platform to create a new generation of inhaled therapeutics. The platform, called iSPERSE(TM) (inhaled small particles easily respirable and emitted), enables drugs to be delivered in inhaled dry powders with unique properties for high drug loading and highly efficient dispersibility and delivery to the airways. iSPERSE can create dry powder formulations with virtually any drug substance, including small molecules, biologics and multi-drug combinations. The company is pursuing both proprietary and partnered applications for iSPERSE. For additional information about Pulmatrix, please visit iSPERSE(TM) is a trademark of Pulmatrix, Inc.

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus